From Boon to Bubble? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

From Boon to Bubble?
Infrastructure must be in place before jumping into outsourcing.


Pharmaceutical Technology


Michelle Hoffman
I was in business school for the peak of the Internet frenzy, so the effect of the Internet on business practices and the economy was a frequent topic for classroom discussion. At the time, every retailer on earth it seemed was scrambling to develop an online purchasing option. But it didn't take long for many of those early online retailing attempts to fail.


Participate in the annual Pharmaceutical Technology Employment Survey.
One of my professors suggested that retailers who were just slapping up online interface were neglecting to develop the sales and distribution infrastructure to support online retailing. So, while orders might have poured in over the Internet, retailers hadn't put in place the extra personnel required to fill the orders. Missing were the personnel to package and ship merchandise. Retailers had also failed to make the necessary arrangements with their shippers to accommodate all of the extra outgoing mail. The net effect was that orders arrived late (or were inaccurately filled, or both). This was particularly devastating during the Christmas holiday season, when holiday presents ordered over the Internet arrived at their destinations long after the holiday was over. Both consumers and sellers felt burned and retreated for a while from online retailing.

Looking back, the lesson seems so obvious but apparently wasn't at the time, or more retailers would have planned appropriately.

This story may serve as a cautionary tale for the outsourcing industry. This year's survey indicates that drugmakers large and small expect to increase their use of contracted services—a substantial boon for contractors. About a quarter of service providers who responded expect their revenues to grow by 20% or more. But as Jim Miller notes in his cover story, this rapid growth may be straining contractors' resources.

"This is especially true for basic infrastructure capabilities like customer service and project management," writes Miller. Is this starting to sound familiar? Of particular (and particularly ominous) note for service providers, the survey uncovers a gap between customer and service provider definitions of service excellence," Miller notes.




So, sellers beware! All evidence indicates that the outsourcing industry will continue to grow—unless, of course, it gets trapped in a bubble.

Michelle Hoffman is editor-in-chief of Pharmaceutical Technology,
.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
43%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
14%
Raw material supply problems
14%
Regulatory restrictions
0%
Business decisions to limit production
29%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here